1,514
Participants
Start Date
March 27, 2024
Primary Completion Date
October 9, 2024
Study Completion Date
November 21, 2024
ARCT-2303
Self-Amplifying RNA COVID-19 vaccine (Omicron XBB.1.5)
Influenza vaccine
Licensed cell-based influenza vaccine
Influenza vaccine, adjuvanted
Licensed influenza vaccine, adjuvanted
Placebo
0.9% saline
Paratus Clinical Canberra, Canberra
Paratus Clinical Central Coast, Central Coast
Sutherland Shire Clinical Research - Walski, Miranda
Australian Clinical Research Network (ACRN), Sydney
Austrials - St. Leonards, Sydney
Emeritus Research Sydney, Sydney
Griffith University Clinical Trials Unit, Sydney
Northern Beaches Clinical Research - Walski, Sydney
Paratus Clinical Blacktown, Sydney
Wollongong Clinical Research, Wollongong
Nucleus Network Brisbane Clinic, Brisbane
Paratus Clinical Brisbane, Brisbane
USC Southbank, Brisbane
USC Morayfield, Morayfield
USC Sippy Down, Sunshine Coast
CMAX Clinical Research, Adelaide
Austrials -Sunshine, Melbourne
Emeritus Research Melbourne, Melbourne
Nucleus Network - Melbourne Clinic, Melbourne
The Peter Doherty Institute for Infection and Immunity, Melbourne
Veritus Research, Melbourne
Clinitrials - Mount Site, Perth
Clínica San Agustín, San José
IICIMED, San José
Organización y centro de investigación clínica Ochoa (OCINCO), Comayagua
Deposito de Medicamentos de Investigación Cousin Agustín (DEMEDICA), San Pedro Sula
Inversiones en Investigación Médica S.A (INVERIME), Tegucigalpa
Tropical Disease Foundation - Putatan Health Center, City of Muntinlupa
Far Eastern University - Nicanor R. M Foundation, Quezon City
Lead Sponsor
Seqirus
INDUSTRY
Novotech (Australia) Pty Limited
INDUSTRY
Arcturus Therapeutics, Inc.
INDUSTRY